⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Seagen Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Seagen Inc.
↗Bothell, Washington, USA
Seagen Inc. (formerly Seattle Genetics) is a global biotechnology company and a recognized leader in the development and commercialization of innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company is best known for its pioneering work in antibody-drug conjugate (ADC) technology, which delivers cell-killing agents directly to cancer cells while minimizing damage to healthy tissue.
In December 2023, Seagen was acquired by Pfizer for approximately $43 billion. This strategic acquisition significantly bolstered Pfizer's oncology portfolio, adding four FDA-approved medicines—Adcetris, Padcev, Tivdak, and Tukysa—and a robust pipeline of early-to-late-stage cancer therapies to Pfizer's existing operations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:1997
Ownership:subsidiary
Status:acquired
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Antibody-drug conjugates (ADC), Monoclonal antibody, Small molecule
Active Trials:248
Trial Phases:Phase 3: 9
FDA Approvals:4
CORPORATE STRUCTURE
Parent Company:Pfizer
Acquired By:Pfizer (2023-12-01)
Key Partnerships:Takeda Pharmaceutical (Brentuximab vedotin), Astellas Pharma (Enfortumab vedotin), Genmab (Tisotumab vedotin), RemeGen
COMPETITION
Position:Leader
Competitors:AstraZeneca, Daiichi Sankyo, Roche
LEADERSHIP
Key Executives:
David R. Epstein - CEO
Scientific Founders:Henry Perry Fell, Jr., Clay Siegall
LINKS
Website:seagen.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Seagen Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.